TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31685500

Group type: EXPERIMENTAL
Intervention: Yoga + usual care
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study: 28420550

Group type: EXPERIMENTAL
Intervention: Caffeine (6mgkg‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 24550171

Group type: EXPERIMENTAL
Intervention: Sarilumab 100 mg every other week
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg every other week
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg every other week
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Sarilumab 100 mg every week
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg every week
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Higher sarilumab doses
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Sarilumab treatment groups
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Sarilumab
Number of subjects: 301
Study: 22951281

Group type: EXPERIMENTAL
Intervention: Structured intervention involving non-GP staff in GP practices
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (30 GP practices without the intervention)
Number of subjects: 60
Study: 20949263

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (Amonate FDC tablets; AS 50 mg and AQ 200 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-fixed dose combination (Arsuamoon AS 50 mg and Flavoquine AQ 200 mg)
Number of subjects: 60
Study: 19395364

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 400 microg every 3 h for five doses
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vaginal misoprostol 400 microg every 3 h for five doses
Number of subjects: 100
Study: 16374601

Group type: EXPERIMENTAL
Intervention: Lorazepam administration
Number of subjects: 0
Study: 15223867

Group type: EXPERIMENTAL
Intervention: Newly developed CAP score
Number of subjects: 67
Study: 11252467

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g Cr + 20 g glucose per day, n=9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (40 g glucose per day, n=9)
Number of subjects: 18
Study: 9253339

Group type: EXPERIMENTAL
Intervention: T4 treatment (L-thyroxine) at a mean dose of 2.8 +/- 0.9 micrograms/kg (0.192 +/- 0.058 mg/day) for a mean duration of 9.2 +/- 5.4 yr
Number of subjects: 17
Study: 8323210

Group type: EXPERIMENTAL
Intervention: Chloroform water 5 ml/day with 1 mg of iodine for 20 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Chloroform water 5 ml/day (placebo)
Number of subjects: 55
Study: 3162993

Group type: EXPERIMENTAL
Intervention: Occlusal equilibration (O group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine stomatognathic treatment including an occlusal splint (S group)
Number of subjects: 30
Study: 30302783

Group type: EXPERIMENTAL
Intervention: Time pressure (n = 40)
Number of subjects: 75
Study: 28760384

Group type: EXPERIMENTAL
Intervention: Relamorelin 10 μg
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Relamorelin 30 μg
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Relamorelin 100 μg
Number of subjects: 393

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393
Study: 25524261

Group type: EXPERIMENTAL
Intervention: Nurse endoscopists
Number of subjects: 731

Group type: COMPARATOR
Intervention: Medical endoscopists
Number of subjects: 731
Study: 23294908

Group type: EXPERIMENTAL
Intervention: ETN+MTX
Number of subjects: 300

Group type: COMPARATOR
Intervention: DMARD+MTX
Number of subjects: 300
Study: 21852813

Group type: COMPARATOR
Intervention: Weight loss intervention (6-month exercise-based program)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Weight regain after weight loss
Number of subjects: 23
Study: 19643544

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 257

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 257

Group type: COMPARATOR
Intervention: Antidepressant
Number of subjects: 257
Study: 17223416

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 0
Study: 15275728

Group type: EXPERIMENTAL
Intervention: LDR intracavitary brachytherapy
Number of subjects: 237

Group type: COMPARATOR
Intervention: HDR intracavitary brachytherapy
Number of subjects: 237
Study: 11207159

Group type: COMPARATOR
Intervention: Diet History Questionnaire (DHQ)
Number of subjects: 1350

Group type: COMPARATOR
Intervention: Prostate, Lung, Colorectal, and Ovarian (PLCO) FFQ
Number of subjects: 1350
Study: 9476038

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (75 mg once daily for 7 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 10
Study: 8201068

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral family intervention (CBFI)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard pediatric care (SPC)
Number of subjects: 44
Study: 3661953

Group type: EXPERIMENTAL
Intervention: Self-taming with suxamethonium (4 mg i.v. after induction, remaining dose applied one minute later)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Pretreatment with pancuronium bromide (2 mg 3 min prior to suxamethonium 1.5 mg/kg)
Number of subjects: 132

Group type: COMPARATOR
Intervention: No pretreatment (control group)
Number of subjects: 132
Study: 31628475

Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content (VLNC) cigarettes (0.4 mg nicotine per g tobacco)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Normal Nicotine Content (NNC) cigarettes (15.8 mg nicotine per g tobacco)
Number of subjects: 58
Study: 29445514

Group type: EXPERIMENTAL
Intervention: Computerised cognitive training using HappyNeuron Pro software, 30 minutes, three times a week for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving social interaction via study and home visits
Number of subjects: 0
Study: 26864207

Group type: EXPERIMENTAL
Intervention: mite allergoid SCIT 20 000 AUeq/ml
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: mite allergoid SCIT 50 000 AUeq/ml
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: mite allergoid SCIT 6667 AUeq/ml
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: mite allergoid SCIT 100 000 AUeq/ml
Number of subjects: 290

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 290
Study: 25072595

Group type: EXPERIMENTAL
Intervention: ACT1 gel formulation plus standard-of-care (SOC) protocols
Number of subjects: 0

Group type: COMPARATOR
Intervention: SOC protocols alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACT1 therapy
Number of subjects: 0
Study: 24276102

Group type: EXPERIMENTAL
Intervention: Novel device for maintaining balance during CPR
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no device)
Number of subjects: 40
Study: 21840002

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (240 mg/day of zinc as zinc gluconate)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 19019730

Group type: EXPERIMENTAL
Intervention: Crataegus extract WS 1442 (900 mg/day)
Number of subjects: 2681

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2681
Study: 16371498

Group type: EXPERIMENTAL
Intervention: Exercise programme with ice applied for 10 minutes after exercises, five times a week for four weeks.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Exercise programme alone (without ice), five times a week for four weeks.
Number of subjects: 40
Study: 12631182

Group type: EXPERIMENTAL
Intervention: Experimental gingivitis with psychological stress (stress group)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Experimental gingivitis without psychological stress (control group)
Number of subjects: 27
Study: 11106919

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (120 mg) plus GHRH (100 microg, i.v.)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg) plus GHRH (100 microg, i.v.)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo plus GHRH (100 microg, i.v.)
Number of subjects: 23
Study: 8827178

Group type: EXPERIMENTAL
Intervention: Epidemiologic studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recent changes in causal factors and diagnostic technological advances
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continued epidemiologic monitoring
Number of subjects: 0
Study: 1545097

Group type: EXPERIMENTAL
Intervention: Inhalative challenge tests with powdered latex gloves
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Specific IgE antibodies to natural latex
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Irradiatively cross‐linked, 'hypoallergenic' latex preparation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Commercial-latex RAST disks (Pharmacia)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Latex IgE RAST and latex skin prick test correlation
Number of subjects: 70
Study: 6375711

Group type: EXPERIMENTAL
Intervention: Mantle radiotherapy followed by 6 courses of adjuvant chemotherapy with mustine, vinblastine, prednisolone and procarbazine (MVPP)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Mantle radiotherapy alone
Number of subjects: 114
Study: 31423757

Group type: EXPERIMENTAL
Intervention: 2WALK (sitting with 2‐min light‐intensity walking breaks every 30 min)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 8WALK (sitting with 8‐min light‐intensity walking breaks every 2 h)
Number of subjects: 15

Group type: COMPARATOR
Intervention: SIT (uninterrupted sitting)
Number of subjects: 15
Study: 29470731

Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Personalized conservative treatment (PCT)
Number of subjects: 64
Study: 26762378

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24574235

Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 195
Study: 22211635

Group type: EXPERIMENTAL
Intervention: Preventive intervention targeting young low-SES disruptive boys (social skills, parental practices, teacher support)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 250
Study: 20811918

Group type: EXPERIMENTAL
Intervention: 8% lidocaine spray 10 min prior to intubation and ETTs lubricated with normal saline (Group E)
Number of subjects: 527

Group type: COMPARATOR
Intervention: 8% lidocaine spray immediately before intubation and ETTs lubricated with normal saline (Group B)
Number of subjects: 527

Group type: COMPARATOR
Intervention: 8% lidocaine spray immediately before intubation and ETTs lubricated with 2% lidocaine gel (Group A)
Number of subjects: 527

Group type: COMPARATOR
Intervention: No lidocaine spray and ETTs lubricated with normal saline (Group C)
Number of subjects: 527

Group type: COMPARATOR
Intervention: No lidocaine spray and ETTs lubricated with 2% lidocaine gel (Group D)
Number of subjects: 527
Study: 17353400

Group type: EXPERIMENTAL
Intervention: Dexamethasone DDS, 700 microg
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Dexamethasone DDS, 350 microg
Number of subjects: 315

Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Dexamethasone DDS (both dosages)
Number of subjects: 315
Study: 14998595

Group type: EXPERIMENTAL
Intervention: Patient education (4h group session + individual nurse and physiotherapist sessions)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 62
Study: 11758183

Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/d + MPA 2 mg/d + Ca‐D 600 mg/d
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CEE 0.3 mg/d + MPA 2 mg/d + Ca‐D 600 mg/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ca‐D 600 mg/d only (control)
Number of subjects: 60
Study: 9731027

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 7670428

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (5-week duration including relaxation training, self-monitoring of stressors, and cognitive coping strategies)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 0
Study: 2507092

Group type: EXPERIMENTAL
Intervention: Asthma nurse visiting homes
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (43 control asthmatics)
Number of subjects: 43
Study: 1096396

Group type: EXPERIMENTAL
Intervention: Propantheline bromide
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 31028155

Group type: EXPERIMENTAL
Intervention: Exposed FDRs (with a family history of non-advanced adenomas)
Number of subjects: 828

Group type: COMPARATOR
Intervention: Unexposed FDRs (without a family history of adenomas)
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Exposed FDRs
Number of subjects: 828

Group type: COMPARATOR
Intervention: Unexposed FDRs
Number of subjects: 828
Study: 31117989

Group type: EXPERIMENTAL
Intervention: ACDC (Adolescent Coping with Depression Course)
Number of subjects: 228

Group type: COMPARATOR
Intervention: UC (Usual Care)
Number of subjects: 228
Study: 28474152

Group type: EXPERIMENTAL
Intervention: Fibular grafting
Number of subjects: 27

Group type: COMPARATOR
Intervention: Core decompression
Number of subjects: 27
Study: 25500307

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10mg daily for 18 weeks)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 404
Study: 24148258

Group type: EXPERIMENTAL
Intervention: Tigatuzumab
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 21640383

Group type: EXPERIMENTAL
Intervention: Pterygium extended removal followed by extended conjunctival transplant
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control eyes (contralateral and otherwise normal)
Number of subjects: 119
Study: 19384265

Group type: EXPERIMENTAL
Intervention: Vitamin supplementation (2 mg of folic acid, 25 mg vitamin B6, and 400 microg of vitamin B12)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Vitamin supplementation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 15860720

Group type: EXPERIMENTAL
Intervention: Humidified CPAP
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 31
Study: 12002496

Group type: EXPERIMENTAL
Intervention: Endoscopic release by the single portal Agee technique
Number of subjects: 25

Group type: COMPARATOR
Intervention: Open release
Number of subjects: 25
Study: 10211633

Group type: EXPERIMENTAL
Intervention: HDL2 and HDL3 levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triglyceride levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HDL2-C/HDL3-C ratio
Number of subjects: 0
Study: 7605876

Group type: EXPERIMENTAL
Intervention: 35 mg Aprosulate b.i.d. s.c.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 70 mg Aprosulate b.i.d. s.c.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 70 mg Aprosulate o.d. + placebo o.d. s.c.
Number of subjects: 0

Group type: COMPARATOR
Intervention: 40 mg Enoxaparin o.d. + placebo o.d. s.c.
Number of subjects: 0
Study: 2083173

Group type: EXPERIMENTAL
Intervention: 900 mg garlic powder per day (equivalent to 2,700 mg of fresh garlic)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 900 mg garlic powder per day
Number of subjects: 40
Study: 392620

Group type: EXPERIMENTAL
Intervention: PGE2 500 micrograms extra-amniotically
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PGE2 3 mg vaginal vault
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3 mg PGE2 vaginal pessary
Number of subjects: 60
Study: 31758268

Group type: EXPERIMENTAL
Intervention: sNiTi (single-file NiTi reciprocal system)
Number of subjects: 34

Group type: COMPARATOR
Intervention: SSH (stainless steel hand file)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: sNiTi
Number of subjects: 34

Group type: COMPARATOR
Intervention: SSH
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: sNiTi and SSH
Number of subjects: 34
Study: 30813440

Group type: EXPERIMENTAL
Intervention: Fish oil (total daily dose: 1728 mg marine triglycerides, of which 588 mg EPA and 412 mg DHA, combined with 200 mg antioxidant, coenzyme Q10)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (olive oil capsules)
Number of subjects: 50
Study: 28912593

Group type: EXPERIMENTAL
Intervention: PTT mixture (200 mg, 69% tocotrienols and 31% α-tocopherol) twice daily for 14 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: PTT mixture (200 mg) postprandial
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo capsules postprandial
Number of subjects: 32
Study: 26468121

Group type: EXPERIMENTAL
Intervention: Zinc-fortified filtered water delivering 2.8 mg Zn (Zn+filter)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Nonfortified filtered water (Filter)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Nonfortified nonfiltered water (Pump)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Zinc-fortified filtered water (Zn+filter)
Number of subjects: 277
Study: 24045780

Group type: EXPERIMENTAL
Intervention: Intrauterine diluted seminal plasma (20% SP in saline)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 21493261

Group type: EXPERIMENTAL
Intervention: Wiping the nasal atomizer tip with 70% isopropanol (group A)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Using single-use plastic atomizer tip guards (group B)
Number of subjects: 34
Study: 20069916

Group type: EXPERIMENTAL
Intervention: beta-tricalcium phosphate (Cerasorb)
Number of subjects: 21

Group type: COMPARATOR
Intervention: bovine-bone hydroxiapatite xenograft (Bio-oss)
Number of subjects: 21
Study: 17241422

Group type: EXPERIMENTAL
Intervention: BTX‐A at 100 U/mL
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: BTX‐A at 33.3 U/mL
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: BTX‐A at 20 U/mL
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: BTX‐A at 10 U/mL
Number of subjects: 80
Study: 15491984

Group type: EXPERIMENTAL
Intervention: STARBRIGHT Hospital Pals group (interactive intervention group)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Modified control group (MCG)
Number of subjects: 79
Study: 11158960

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 27

Group type: COMPARATOR
Intervention: Real acupuncture and Sham acupuncture
Number of subjects: 27
Study: 9784087

Group type: EXPERIMENTAL
Intervention: Hypericum perforatum (St John's wort) 0.9 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Hypericum perforatum (St John's wort) 1.8 mg
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 7929810

Group type: EXPERIMENTAL
Intervention: Endothelin-1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 12
Study: 2894883

Group type: EXPERIMENTAL
Intervention: Nifedipine (maximum dose 40 mg twice a day)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Atenolol (maximum dose 100 mg once a day)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Fixed combination of atenolol 50 mg and nifedipine 20 mg once daily for eight weeks
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 410

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 410
Study: 29974143

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin infusion at increasing doses up to 40 μg/min
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous nitroglycerin infusion alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan 200 mg bid
Number of subjects: 40
Study: 26946991

Group type: EXPERIMENTAL
Intervention: Couples Health CoOp (CHC)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Comparison arm
Number of subjects: 290

Group type: COMPARATOR
Intervention: WHC/MHC arm
Number of subjects: 290
Study: 25582850

Group type: EXPERIMENTAL
Intervention: NaFeEDTA-fortified soy sauce (6 mg Fe)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FeSO₄-fortified soy sauce (6 mg Fe)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No iron-fortified soy sauce (control group)
Number of subjects: 60
Study: 23021797

Group type: EXPERIMENTAL
Intervention: Pioglitazone add-on
Number of subjects: 98

Group type: COMPARATOR
Intervention: Sulfonylureas add-on
Number of subjects: 98
Study: 20677441

Group type: EXPERIMENTAL
Intervention: Placebo effect
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug effect
Number of subjects: 0
Study: 18800883

Group type: EXPERIMENTAL
Intervention: Inhaled sodium pyruvate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15985101

Group type: EXPERIMENTAL
Intervention: Delayed sumatriptan injection (6 mg) followed by ketorolac infusion (two 15-mg boluses) 4 hours after onset of attack.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Delayed ketorolac monotherapy (two 15-mg boluses) 4 hours after onset of attack.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Infusion of COX1/COX2 inhibitors (ketorolac 0.4 mg/kg or indomethacin 1 mg/kg) in rats.
Number of subjects: 28
Study: 12455318

Group type: EXPERIMENTAL
Intervention: Metamizol (2 g intravenous)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propacetamol (2 g intravenous)
Number of subjects: 60
Study: 10528949

Group type: EXPERIMENTAL
Intervention: One-to-One midwifery practice
Number of subjects: 1403

Group type: COMPARATOR
Intervention: Conventional maternity care
Number of subjects: 1403
Study: 7670399

Group type: EXPERIMENTAL
Intervention: Detection of malignant B cells in PBSC samples after chemotherapy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Beta 2 microglobulin serum level correlation
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Grafting of patients
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Prognosis of patients with PBSC contamination
Number of subjects: 22
Study: 2289218

Group type: EXPERIMENTAL
Intervention: 1,200 mg of citicoline daily plus usual dose of levodopa (mean, 381 mg daily)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Half their usual dose of levodopa (mean, 196 mg daily) plus citicoline
Number of subjects: 85